Net Cash Provided by (Used in) Financing Activities of Monopar Therapeutics from 31 Dec 2016 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Monopar Therapeutics quarterly and annual Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Dec 2016 to 31 Mar 2025.
  • Monopar Therapeutics Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $115,682, a 104% decline year-over-year.
  • Monopar Therapeutics annual Net Cash Provided by (Used in) Financing Activities for 2024 was $59,292,257, a 2825% increase from 2023.
  • Monopar Therapeutics annual Net Cash Provided by (Used in) Financing Activities for 2023 was $2,027,227, a 6067% increase from 2022.
  • Monopar Therapeutics annual Net Cash Provided by (Used in) Financing Activities for 2022 was $32,873, a 100% decline from 2021.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

Monopar Therapeutics Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $115,682 -$3,297,563 -104% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q1 2024 $3,181,881 +$2,377,083 +295% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q1 2023 $804,798 +$821,464 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q1 2022 $16,666 -$10,937,956 -100% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q1 2021 $10,921,290 +$10,413,246 +2050% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q1 2020 $508,044 +$521,899 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1
Q1 2019 $13,855 -$13,855 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q1 2018 $0 -$990,002 -100% 01 Jan 2018 31 Mar 2018 10-Q 10 May 2019 2019 Q1
Q1 2017 $990,002 01 Jan 2017 31 Mar 2017 10-Q 11 May 2018 2018 Q1

Monopar Therapeutics Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $59,292,257 +$57,265,030 +2825% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 $2,027,227 +$1,994,354 +6067% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $32,873 -$10,846,664 -100% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 $10,879,537 +$2,697,417 +33% 01 Jan 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
2020 $8,182,120 -$1,165,291 -12% 01 Jan 2020 31 Dec 2020 10-K 24 Mar 2022 2021 FY
2019 $9,347,411 +$9,553,681 01 Jan 2019 31 Dec 2019 10-K 25 Mar 2021 2020 FY
2018 $206,270 -$9,742,659 -102% 01 Jan 2018 31 Dec 2018 10-K 27 Mar 2020 2019 FY
2017 $9,536,389 +$8,273,889 +655% 01 Jan 2017 31 Dec 2017 10-K 26 Feb 2019 2018 FY
2016 $1,262,500 01 Jan 2016 31 Dec 2016 10-K 26 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.